Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD Registries

Heart transplantation (HT) is the gold standard therapy for advanced heart failure (ADHF), and LVADs as destination therapy are an option in non-HT candidates. Most patients with ADHF never receive HT or an LVAD, so alternative strategies are needed. Intermittent levosimendan can reduce HF hospitali...

Descripción completa

Detalles Bibliográficos
Autores: Dobarro, David, Raposeiras-Roubin, Sergio, Almenar-Bonet, Luis, Solé-González, Eduard, Padilla-Lopez, Mireia, Diez-Lopez, Carles, Castrodeza, Javier, García-Cosío, Maria Dolores, Cobo-Marcos, Marta, Tobar, Javier, Codina, Pau, Lopez-Fernandez, Silvia, Pastor, Francisco, Rangel-Sousa, Diego, Barge-Caballero, Eduardo, Diaz-Molina, Beatriz, Barrio-Rodriguez, Alfredo, Burgos-Palacios, Virginia, Álvarez-García, Jesús, González-Fernández, Oscar, Grau-Sepúlveda, Andrés, Garcia-Pinilla, José Manuel, Ruiz-Bustillo, Sonia, Mendez-Fernández, Ana B, Vaqueriza-Cubillo, David, Sagasti-Aboitiz, Igor, Rodriguez-Santamarta, Miguel, Lozano-Bahamonde, Ainara, Abecia, Ana, Gómez-Otero, Inés, Marzoa, Raquel, González-Babarro, Eva, Gómez-Bueno, Manuel, Gonzalez-Costello, José
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/21686
Acceso en línea:https://hdl.handle.net/20.500.13003/21686
Access Level:acceso abierto
id ES_07e4fea26bb2ae1606d8d71b1c9bc261
oai_identifier_str oai:docusalut.com:20.500.13003/21686
network_acronym_str ES
network_name_str España
repository_id_str
spelling Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD RegistriesDobarro, DavidRaposeiras-Roubin, SergioAlmenar-Bonet, LuisSolé-González, EduardPadilla-Lopez, MireiaDiez-Lopez, CarlesCastrodeza, JavierGarcía-Cosío, Maria DoloresCobo-Marcos, MartaTobar, JavierCodina, PauLopez-Fernandez, SilviaPastor, FranciscoRangel-Sousa, DiegoBarge-Caballero, EduardoDiaz-Molina, BeatrizBarrio-Rodriguez, AlfredoBurgos-Palacios, VirginiaÁlvarez-García, JesúsGonzález-Fernández, OscarGrau-Sepúlveda, AndrésGarcia-Pinilla, José ManuelRuiz-Bustillo, SoniaMendez-Fernández, Ana BVaqueriza-Cubillo, DavidSagasti-Aboitiz, IgorRodriguez-Santamarta, MiguelLozano-Bahamonde, AinaraAbecia, AnaGómez-Otero, InésMarzoa, RaquelGonzález-Babarro, EvaGómez-Bueno, ManuelGonzalez-Costello, JoséHeart transplantation (HT) is the gold standard therapy for advanced heart failure (ADHF), and LVADs as destination therapy are an option in non-HT candidates. Most patients with ADHF never receive HT or an LVAD, so alternative strategies are needed. Intermittent levosimendan can reduce HF hospitalizations in ADHF patients in the short term. It is uncertain whether the results of the comparison of inotropes with older-generation LVADs would have the same outcomes in the current era of ADHF patients treated with levosimendan, who are less sick but older. In this paper, we compare the use of two therapeutic strategies for end-stage HF in patients who are not candidates for HT: repetitive intermittent levosimendan vs. LVAD as destination therapy. To do so, we compare two multicenter cohorts of real-life patients from Spain: the LEVO-D registry and the REGALAD registry. In total, 715 patients coming from the two registries were found: 403 from LEVO-D and 312 from REGALAD. Non-adjusted median survival was shorter for LEVO-D patients, with the benefit for the LVADs seen only after the first year of therapy. The survival advantage for the LVAD cohort was also true after analysis of the matched cohort but, as in the non-matched analysis, the survival benefit was mainly shown after one year of follow-up. We conclude that in elderly ADHF non-HT candidates, LVAD therapy offers significantly better long-term outcomes when compared to intermittent levosimendan; thus, it should be considered in carefully selected candidates. On the other hand, in poor LVAD candidates or highly comorbid patients, intermittent inotropic support with levosimendan could be a reasonable alternative to LVAD, as 1-year outcomes are similar.MDPI20242024-11-2920242024-11-29research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.13003/21686reponame:Docusalutinstname:Conselleria de Salut i Consum del Govern de les Illes BalearsInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:docusalut.com:20.500.13003/216862026-06-22T12:44:07Z
dc.title.none.fl_str_mv Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD Registries
title Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD Registries
spellingShingle Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD Registries
Dobarro, David
title_short Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD Registries
title_full Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD Registries
title_fullStr Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD Registries
title_full_unstemmed Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD Registries
title_sort Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD Registries
dc.creator.none.fl_str_mv Dobarro, David
Raposeiras-Roubin, Sergio
Almenar-Bonet, Luis
Solé-González, Eduard
Padilla-Lopez, Mireia
Diez-Lopez, Carles
Castrodeza, Javier
García-Cosío, Maria Dolores
Cobo-Marcos, Marta
Tobar, Javier
Codina, Pau
Lopez-Fernandez, Silvia
Pastor, Francisco
Rangel-Sousa, Diego
Barge-Caballero, Eduardo
Diaz-Molina, Beatriz
Barrio-Rodriguez, Alfredo
Burgos-Palacios, Virginia
Álvarez-García, Jesús
González-Fernández, Oscar
Grau-Sepúlveda, Andrés
Garcia-Pinilla, José Manuel
Ruiz-Bustillo, Sonia
Mendez-Fernández, Ana B
Vaqueriza-Cubillo, David
Sagasti-Aboitiz, Igor
Rodriguez-Santamarta, Miguel
Lozano-Bahamonde, Ainara
Abecia, Ana
Gómez-Otero, Inés
Marzoa, Raquel
González-Babarro, Eva
Gómez-Bueno, Manuel
Gonzalez-Costello, José
author Dobarro, David
author_facet Dobarro, David
Raposeiras-Roubin, Sergio
Almenar-Bonet, Luis
Solé-González, Eduard
Padilla-Lopez, Mireia
Diez-Lopez, Carles
Castrodeza, Javier
García-Cosío, Maria Dolores
Cobo-Marcos, Marta
Tobar, Javier
Codina, Pau
Lopez-Fernandez, Silvia
Pastor, Francisco
Rangel-Sousa, Diego
Barge-Caballero, Eduardo
Diaz-Molina, Beatriz
Barrio-Rodriguez, Alfredo
Burgos-Palacios, Virginia
Álvarez-García, Jesús
González-Fernández, Oscar
Grau-Sepúlveda, Andrés
Garcia-Pinilla, José Manuel
Ruiz-Bustillo, Sonia
Mendez-Fernández, Ana B
Vaqueriza-Cubillo, David
Sagasti-Aboitiz, Igor
Rodriguez-Santamarta, Miguel
Lozano-Bahamonde, Ainara
Abecia, Ana
Gómez-Otero, Inés
Marzoa, Raquel
González-Babarro, Eva
Gómez-Bueno, Manuel
Gonzalez-Costello, José
author_role author
author2 Raposeiras-Roubin, Sergio
Almenar-Bonet, Luis
Solé-González, Eduard
Padilla-Lopez, Mireia
Diez-Lopez, Carles
Castrodeza, Javier
García-Cosío, Maria Dolores
Cobo-Marcos, Marta
Tobar, Javier
Codina, Pau
Lopez-Fernandez, Silvia
Pastor, Francisco
Rangel-Sousa, Diego
Barge-Caballero, Eduardo
Diaz-Molina, Beatriz
Barrio-Rodriguez, Alfredo
Burgos-Palacios, Virginia
Álvarez-García, Jesús
González-Fernández, Oscar
Grau-Sepúlveda, Andrés
Garcia-Pinilla, José Manuel
Ruiz-Bustillo, Sonia
Mendez-Fernández, Ana B
Vaqueriza-Cubillo, David
Sagasti-Aboitiz, Igor
Rodriguez-Santamarta, Miguel
Lozano-Bahamonde, Ainara
Abecia, Ana
Gómez-Otero, Inés
Marzoa, Raquel
González-Babarro, Eva
Gómez-Bueno, Manuel
Gonzalez-Costello, José
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
description Heart transplantation (HT) is the gold standard therapy for advanced heart failure (ADHF), and LVADs as destination therapy are an option in non-HT candidates. Most patients with ADHF never receive HT or an LVAD, so alternative strategies are needed. Intermittent levosimendan can reduce HF hospitalizations in ADHF patients in the short term. It is uncertain whether the results of the comparison of inotropes with older-generation LVADs would have the same outcomes in the current era of ADHF patients treated with levosimendan, who are less sick but older. In this paper, we compare the use of two therapeutic strategies for end-stage HF in patients who are not candidates for HT: repetitive intermittent levosimendan vs. LVAD as destination therapy. To do so, we compare two multicenter cohorts of real-life patients from Spain: the LEVO-D registry and the REGALAD registry. In total, 715 patients coming from the two registries were found: 403 from LEVO-D and 312 from REGALAD. Non-adjusted median survival was shorter for LEVO-D patients, with the benefit for the LVADs seen only after the first year of therapy. The survival advantage for the LVAD cohort was also true after analysis of the matched cohort but, as in the non-matched analysis, the survival benefit was mainly shown after one year of follow-up. We conclude that in elderly ADHF non-HT candidates, LVAD therapy offers significantly better long-term outcomes when compared to intermittent levosimendan; thus, it should be considered in carefully selected candidates. On the other hand, in poor LVAD candidates or highly comorbid patients, intermittent inotropic support with levosimendan could be a reasonable alternative to LVAD, as 1-year outcomes are similar.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-11-29
2024
2024-11-29
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.13003/21686
url https://hdl.handle.net/20.500.13003/21686
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Docusalut
instname:Conselleria de Salut i Consum del Govern de les Illes Balears
instname_str Conselleria de Salut i Consum del Govern de les Illes Balears
reponame_str Docusalut
collection Docusalut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403010444034048
score 15,81155